The European Commission has granted marketing authorisation to a treatment reducing the risk of measles in non-vaccinated patients. 

Privigen, developed by CSL, is a human immunoglobulin therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended. 

The therapy is prepared from screened donor plasma and is indicated to provide pre- and post-exposure prophylaxis for susceptible high-risk individuals. This includes immunocompromised patients, pregnant women without evidence of immunity, and infants or other vulnerable contacts with high unmet needs, for whom active immunisation is contraindicated or not recommended. 

Immunoglobulin therapy works by providing concentrated antibodies that can neutralise the measles virus after exposure, which may provide passive antibody protection following exposure. 

Statistics indicate measles in on the rise in Europe, with the European Centre for Disease Prevention and Control reporting the number of cases were twice as high in 2025 as in 2023. 

“While vaccination remains the most effective way to prevent measles, outbreaks across Europe highlight the urgent need for additional tools to protect those at risk,” said Emmanuelle Lecomte Brisset, Head of Global Regulatory Affairs and Safety at CSL.  

“This approval ensures clinicians have access to an immunoglobulin option where passive protection may be considered.”